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There are multiple sources of reactive oxygen species (ROS) in the cell. As a major site of ROS production,
mitochondria have drawn considerable interest because it was recently discovered that mitochondrial ROS (mtROS)
directly stimulate the production of proinflammatory cytokines and pathological conditions as diverse as
malignancies, autoimmune diseases, and cardiovascular diseases all share common phenotype of increased mtROS
production above basal levels. Several excellent reviews on this topic have been published, but ever-changing new
discoveries mandated a more up-to-date and comprehensive review on this topic. Therefore, we update recent
understanding of how mitochondria generate and regulate the production of mtROS and the function of mtROS
both in physiological and pathological conditions. In addition, we describe newly developed methods to probe or
scavenge mtROS and compare these methods in detail. Thorough understanding of this topic and the application
of mtROS-targeting drugs in the research is significant towards development of better therapies to combat
inflammatory diseases and inflammatory malignancies.
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Free radicals and other ROS are generated in a wide
range of normal physiological conditions. However, ROS
also participate in many pathological conditions includ-
ing cardiovascular diseases, malignancies, autoimmune
diseases, and neurological degenerative diseases. Despite
intensive investigations in this field, current anti-oxidant
therapeutics are not clinically effective in combating
these pathological conditions suggesting that our under-
standing of this field is limited, and there is a need to
narrow the “knowledge gap” in order to develop more
effective new therapies [1]. Although ROS are historic-
ally considered toxic by-products of cellular metabolism,
recent studies have suggested that cells “have learned” to
harness the power of ROS for cell signaling purposes. In
analogous to phosphorylation modification of proteins,
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reproduction in any medium, provided the orevents of oxidation modification of proteins by ROS. In-
deed, there are multiple sources of ROS in the cell in-
cluding nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (NOX) [2], xanthine oxidase (XO),
uncoupling of nitric oxide synthase (NOS), cytochrome
P450, and mitochondrial electron transport chain
(ETC). Among these potential sources, however, mtROS
have drawn increasing attentions because it was recently
discovered that mtROS directly contribute to inflamma-
tory cytokine production and innate immune responses
[3] by activation of newly characterized RIG-I-like recep-
tors (RLRs) [4], inflammasomes [5], and mitogen-
activated protein kinases (MAPK) [6].
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in the western world. Nearly
75% of the CVD-related death results from atheroscler-
osis which is found in 80-90% of Americans over the age
of 30. Early atherosclerotic lesions can be detected in
youths as young as 7 years of age [7,8]. As a form of
chronic autoimmune inflammatory condition associated
with specific CVD risk factors, development of athero-
sclerosis is fueled by aberrant response of the innatehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cytokines [9,10]. A recent progress in characterizing
mtROS has led to the generation of a new paradigm, in
which blockade of mtROS production may serve as a
promising therapy for inhibiting proinflammatory cyto-
kine production and in turn atherosclerosis. Although
there were several excellent reviews published 5 years
ago in this topic [11,12], new recent discoveries have
mandated a more up-to-date and comprehensive review
[13-15]. Therefore, in this review we consider current
understandings of several compelling questions: 1) how
mitochondria generate and dispose of ROS; 2) how pro-
duction of mtROS is regulated; and 3) what signaling
pathways are targeted by mtROS. In addition, we de-
scribe the methods to probe mtROS and analyze the
merits and flaws of these different methods. Further-
more, we demonstrate how mtROS regulate important
vascular function in physiological conditions and activate
inflammatory pathways in response to CVD risk factors.
In-depth understanding of these processes is critical to
developing novel therapeutic drugs against chronic in-
flammatory conditions such as atherosclerosis.
Production of mtROS
Mitochondria have a four-layer structure, including
outer mitochondrial membrane, intermembrane space,
inner mitochondrial membrane and matrix (Figure 1).
Generation of mtROS mainly takes place at the ETC lo-
cated on the inner mitochondrial membrane during the
process of oxidative phosphorylation (OXPHOS). Oxida-
tive phosphorylation is an essential cellular process that
uses oxygen and simple sugars to create adenosine tri-
phosphate (ATP), which is the cell's main energy source.I III
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Figure 1 Production and disposal of mtROS. Electrons (e-) donated from
ultimately reduce O2 to form H2O at complex IV. MtROS are produced from
III. O2
.- is produced within matrix at complex I, whereas at complex III O2
.- is
Once generated, O2
.- is dismutated to H2O2 by superoxide dismutase 1 (SO
Afterwards, H2O2 is fully reduced to water by glutathione peroxidase (GPX)
mtROS. OM: outer membrane; IM: inner membrane.Five big protein complexes are involved in this process
(HUGO Gene Nomenclature Committee Website,
Table 1). These ETC complexes are named complex I
(NADH dehydrogenase (ubiquinone), 45 protein sub-
units), complex II (succinate dehydrogenase, 4 protein
subunits), complex III (ubiquinol-cytochrome c reduc-
tase, 10 protein subunits), complex IV (cytochrome c
oxidase, 19 protein subunits), and complex V (ATP syn-
thase, 19 protein subunits). Electrons donated from
nicotine adenine dinucleotide (NADH) at complex I and
flavin adenine dinucleotide (FADH2) at complex II pass
through ETC and ultimately reduce O2 to water at com-
plex IV. Meanwhile, positively charged protons (H+) are
actively being pumped from the mitochondrial matrix
into the intermembrane space, resulting in the increased
negative charges in the mitochondrial matrix and the
upregulated positive charges in the intermembrane
space, and thus creating a mitochondrial membrane po-
tential (Δψm) across the inner mitochondrial membrane.
This proton-motive force allows complex V - ATP syn-
thase (ATP-ase) to generate ATP from adenosine di-
phosphate (ADP) and inorganic phosphate when
protons re-enter the mitochondrial matrix through the
complex V enzyme. However, either by accident or by
design, the process of ETC is not perfect. Leakage of
electrons at complex I and complex III leads to partial
reduction of oxygen to form superoxide (O2
.-). It has
been estimated that 0.2% to 2.0% of O2 consumed by
mitochondria generates O2
.- [11]. There are three leak
events: complex I leaks O2
.- towards the mitochondrial
matrix, while complex III leaks O2
.- towards both the
intermembrane space and mitochondrial matrix [11,16].
Subsequently, O2


















NADH and FADH2 pass through the electron transport chain and
the leakage of e- to form superoxide (O2
.-) at complex I and complex
released towards both the matrix and the intermembrane space.
D1) in the intermembrane space and by SOD2 in the matrix.
. Both O2
.- and H2O2 produced in this process are considered as
Table 1 Mitochondrial DNA (mtDNA) and nuclear DNA
(nDNA) encoded subunits for the electron transport chain
Complex
Genome I II III IV V Total
mtDNA 7 0 1 3 2 13
nDNA 38 4 9 16 17 84
Total 45 4 10 19 19 97
Source: www.genenames.org/genefamilies/mitocomplex#coml.
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dismutase 2 (SOD2) in mitochondrial matrix and
superoxide dismutase 1 (SOD1) in mitochondrial
intermembrane space. Collectively, both O2
.- and H2O2
generated in this process are considered as mtROS.
These two mtROS have different fates however. Given
its electrophilic property and short half-life, O2
.- can
hardly pass through mitochondrial outer membrane and
unlikely to become the candidate of signaling transduc-
tion molecule in the cell. Instead, O2
.- can undergo
radical-radical reaction with nitric oxide (NO) to form
peroxynitrite (ONOO2
.-) within mitochondria, a detri-
mental oxidant capable of induction of DNA damage,
disruption of mitochondrial integrity, and irreversible
modification of proteins [11]. In contrast, H2O2 is
electrophobic and more stable than O2
.-. Indeed, the
concentrations of H2O2 in mitochondria are 100 times
greater than that of O2
.- [17]. These properties render
mitochondrial H2O2 an ideal signaling molecule in the
cells.
Scavenging of mtROS
Owing to the high reactivity and toxicity of mtROS,
mammalian cells have evolved a number of antioxidant
enzyme systems to scavenge mtROS as soon as they are
generated. As mentioned in the previous section, the
SOD family of antioxidant enzymes catalyze the
dismutation of O2
.- to H2O2. Subsequently, H2O2 is
quickly reduced to water by two other enzymes, catalase
and glutathione peroxidase (GPx) (Figure 1). It should
be noted that all the mitochondrial antioxidant enzymes
are encoded by the nuclear genome but not mitochon-
drial genome, and these enzymes are subsequently
imported into the mitochondria after their protein
translation.
SODs
Three isoforms of SOD have been identified, including
SOD1/copper-zinc SOD (CuZn-SOD), SOD2/manganese
SOD (Mn-SOD), and extracellular SOD3 (EC-SOD).
SOD1 is widely distributed throughout the cell cyto-
plasm, nucleus, and intermembrane space of mitochon-
dria [18]. SOD2 is expressed only in the mitochondrial
matrix [18], and SOD3 is found in the extracellularspace. The physiological importance of SOD2 is high-
lighted by the finding that in contrast to other SOD
isoforms, the deficiency of SOD2 causes early neonatal
death in gene knockout mice [19] and endothelial dys-
function in carotid artery of proatherogenic apolipopro-
tein E (ApoE)-deficient mice [11,20].
Catalase
Catalase is a heme-containing tetramer of four polypep-
tide chains that reduces H2O2 to water. Although cata-
lase is highly efficient at reducing hydrogen peroxide, it
may not play a central role in scavenging ROS in the
mitochondria since it is localized mainly in peroxisomes
except that rat heart mitochondria does partially de-
pend on catalase to scavenge ROS [21]. Nevertheless,
overexpression of catalase in ApoE−/− mice results in
the retardation of atherosclerosis [22]. In addition,
overexpression of catalase in the mitochondria de-
creased oxidative damage, inhibited cardiac pathology,
and extended the lifespan of mice [23]. These results sug-
gest the importance of catalase in suppressing cardiovas-
cular inflammation and damage and atherosclerosis.
GPx
GPx catalyzes the reductive inactivation of H2O2 using
reduced glutathione (GSH) as a cofactor. GSH is a tripep-
tide containing of three amino acid residues including glu-
tamate, cysteine, and glycine. During the process of
reducing H2O2, GSH is oxidized to oxidized glutathione
(GSSG). GSSG is then recycled back to GSH by the en-
zyme glutathione reductase (GR) using NADPH as a sub-
strate [13]. Thus, the maintenance of GSH for optimal
scavenging capacity is dependent on the bioavailability of
NADPH stores. Deficiency of GPx results in acceleration
of atherogenesis in ApoE−/− mice, highlighting the im-
portance of glutathione peroxidase in suppressing vascular
inflammation and atherosclerosis [24].
Peroxiredoxin
Peroxiredoxins are a family of antioxidant enzymes that
regulate cytokine-induced peroxide levels and mediate
signal pathways [25]. There are six peroxiredoxins in this
family. Importantly, H2O2 has the highest affinity to
peroxiredoxin 2 (100%), then to GSH (<0.01%), to
Cdc25B (<0.0001%) and to protein tyrosine phosphatase
1B (<0.000001%), demonstrating the importance of
peroxiredoxins [1]. Overexpression of mitochondrial
matrix peroxiredoxin (peroxiredoxin-3) prevents left
ventricular remodeling and failure after myocardial in-
farction in mice [26].
Thioredoxins
Thioredoxins are small proteins that play a variety of roles
depending upon binding interactions and oxidoreductase
Figure 2 Regulation of mtROS production. A number of factors
including mitochondrial membrane potential (Δψm), metabolic state
of mitochondrial, O2 concentration regulate the production of
mtROS. Non-mitochondrial generated ROS can also augment mtROS
production, a process known as “ROS-induced ROS”. Meanwhile,
transcription factor STAT3 has recently been found to suppress
mtROS production independent of its nuclear factor activity.
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drial protein. Trx2 deficiency results in embryonic lethal
at gestational day 10.5 and embryos show massive apop-
tosis. The timing coincides with the maturation of mito-
chondrial function. In addition, Trx2 protects against
vascular pathology in the ApoE-knockout mouse model
for CVD [27]. Furthermore, the accumulated data strongly
support a role for Trx2 in protecting against oxidant-
induced apoptosis via regulating mitochondrial permeabil-
ity transition [28].
Synthetic mtROS scavengers
Although several natural antioxidants including vitamin E
have been shown to decrease mtROS; however their ef-
fectiveness was limited as they did not accumulated within
mitochondria nor could they cross the blood–brain bar-
rier efficiently [29,30]. To address this issue, several syn-
thetic mtROS scavengers have been developed. These
compounds easily pass through all biological membranes,
including the blood–brain barrier, into cells and tissues af-
fected by mtROS [31]. The first targeted ROS scavenger is
MitoVit-E in which vitamin E is covalently attached to a
triphenylphosphonium cation [32]. MitoVit-E decreases
ROS production and apoptosis in aortic endothelial cells
induced by oxidative stress, but it is ineffective against
hypoxic–ischemic striatal injury in neonatal rats [33]. The
second ROS scavenger is MitoQ10 which consists of a
lipophilic triphenylphosphonium cation covalently at-
tached via an aliphatic linker to a ubiquinone derivative
[34]. After detoxifying an oxidant species, MitoQ10 can
be regenerated by the respiratory chain. MitoQ10 inhibits
mitochondrial oxidative damage in rodent models of car-
diac ischemia and reperfusion injury [33]. Moreover, the
results of animal studies using MitoQ10 or an alternative
compound termed SkQ1 are promising. When perfused
through isolated heart preparations or fed to rats, SkQ1
is able to reduced ischemia-induced arrhythmia and
infarct size; SkQ1 is used at a concentration that is an
astounding one million fold lower than that of MitoQ.
The results of ongoing clinical studies are awaited with
great interest [33].
Regulation of mtROS
ROS production in mitochondria is determined by the
rates of both mtROS production and disposal, and it is
regulated by a number of factors, such as mitochondrial
membrane potential, metabolic state of mitochondria,
and O2 levels [35] (Figure 2).
Mitochondrial membrane potential (Δψm)
As described above, Δψm is created when protons are pumped
from the mitochondrial matrix to the intermembrane space as
electrons pass through the ETC. The concept that higher
(more polarized) Δψm is associated with greater mtROSgeneration is widespread in literature, and this is thought to
be due to the slowed electron transport [11,20]. This idea is
supported by the observation of decreased ROS generation
when Δψm is dissipated by either chemical uncouplers [36],
such as carbonyl cyanide p-(tri-fluromethoxy)phenyl-
hydrazone (FCCP) [37], or overexpression of mitochondrial
uncoupling proteins (UCPs) [38]. However, it has also been
shown that uncoupling of the mitochondrial ETC in
cardiomyocytes using chemical uncouplers in fact increased
ROS accumulation [15]. To reconcile this obvious discrep-
ancy, a redox-optimized ROS balance hypothesis is pro-
posed, stating that physiological ROS signaling occurs
within an optimized mitochondrial membrane potential,
and oxidative stress can happen at either the extreme of
high Δψm or low Δψm [15]. This hypothesis is based on the
fact that the redox couples involved in substrate oxidation
(NADH) are closely linked to the redox couples involved in
antioxidant defenses (NADPH). Hence, it is vital to balance
an adequate level of Δψm to maintain matrix NADPH ra-
ther than NADP+, which is necessary for mitochondrial
antioxidant enzyme systems. In other word, an increase in
mitochondrial uncoupling of the ETC can increase ROS
production primarily because the antioxidant system of the
cell is compromised.
Metabolic state of mitochondria
Metabolic state of mitochondria is another important
factor that modulates mtROS production. The concept
of metabolic states of mitochondria was proposed by
Britton Chance and G.R. Williams in 1955 [39]. State I is
the first respiratory state observed when isolated mito-
chondria are added to mitochondrial respiration medium
containing oxygen and inorganic phosphate, but no ADP
and no reduced respiratory substrates [39]. In State I,
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defined endogenous substrates, which are oxidized and
slowly exhausted. State II is the substrate-limited state of
residual oxygen consumption, after addition of ADP to
isolated mitochondria suspended in mitochondrial res-
piration medium in the absence of reduced substrates
[39]. State III respiration is the ADP-stimulated respir-
ation of isolated coupled mitochondria in the presence
of high ADP and phosphate concentrations, supported
by a defined substrate or substrate combination at satur-
ating oxygen levels [39]. State IIIu (u for uncoupled) has
been used frequently in bioenergetics on the fundamen-
tal difference between OXPHOS capacity and non-
coupled ETS capacity. State IV is the respiratory state
obtained in isolated mitochondria after State III, when
added ADP is phosphorylated completely to ATP driven
by electron transfer from defined respiratory substrates
to O2 [39]. State V is the respiratory state obtained in a
protocol with isolated mitochondria after a sequence of
State I to State IV, when the concentration of O2 is de-
pleted in the closed oxygraph chamber and zero oxygen
(the anaerobic state) is reached [39]. The State V is de-
fined in the original publication in two ways - State V
may be obtained by antimycin A treatment and by an-
aerobiosis. Resting mitochondria (State IV) are charac-
terized by low electron flow and ATP synthesis, low
rates of O2 consumption, and high NADH/NAD
+ ratio
leading to high ROS production. When mitochondria
are synthesizing ATP (State III), the opposite happens
(high electron flow and ATP synthesis, high rates of O2
consumption, high NADH/NAD+) which results in
lower ROS production [40].
Importantly, endogenous modulators such as NO and
Ca2+ can regulate the production of mtROS by regulat-
ing the metabolic states of mitochondria. NO is a diffus-
ible gas synthesized by three NOS enzymes including
endothelial NOS (eNOS), inducible NOS (iNOS) and
neuronal NOS (nNOS). These three enzymes share
50–60% homology at the amino acid sequence and have
an N-terminal oxygenase domain with heme-, L-arginine-,
tetrahydrobiopterin (BH4)-binding domains, a central cal-
modulin (CaM)-binding region, and a C-terminal reduc-
tase domain with NADPH, FAD, and FMN binding sites
[41]. The identification of NOS in the mitochondria [42]
and the fact that the ETC has several NO. reactive-redox
metal centers [11] strongly argue NO’s role as an import-
ant modulator of mtROS production. NO can modulate
mitochondrial respiration and oxygen consumption
through reversible binding and inhibition at complex IV,
leading to the accumulation of NADH and increases in
ROS production [43]. Mitochondria also participate in
Ca2+ homeostasis by serving as a high-capacity, low-
affinity transient Ca2+ store. Unlike NO, it seems that a
moderate increase in mitochondrial Ca2+ stimulates therate of electron flow in the ETC and thus decreases
mtROS generation [44]. However, it should be noted that
mitochondrial Ca2+ overload increases mtROS produc-
tion, which is independent of the metabolic states of mito-
chondria [45].
O2 concentration
MtROS production also depends on O2 concentration. As
cellular O2 concentration increases, the rate of mtROS
production increases linearly [46]. However, during hyp-
oxia, a paradoxical increase in mtROS release was
reported [47]. This mtROS release appears to come from
complex III and functions as a regulator of hypoxia-
inducible factor 1α (HIF-1α). Nevertheless, the precise
molecular basis underlying the seemingly controversial re-
lationship between ambient oxygen levels and mtROS
production remains obscure. The redox-optimized ROS
balance hypothesis mentioned previously can be used to
account for this discrepancy. It is postulated that hypoxic
cells would exhibit high Δψm and augmented mtROS pro-
duction due to the low electron flow [15]. In this setting,
the increased generation of mtROS could then be relieved
by overexpressing mitochondrial UCPs [48].
Mitochondrial mass
MtROS may be additionally altered by mitochondrial
mass. Theoretically, the level of mtROS generation
should be positively correlated to the quantity of mito-
chondria in the cell. Nevertheless, it has been shown
that the mitochondrial biogenesis factor peroxisome-
proliferator-activated receptor-γ coactivator 1α (PGC1α)
not only increases mitochondrial mass but also increases
the expression of many antioxidant enzymes including
GPx and SOD2 [49]. It therefore stands to reason that
mitochondrial mass is not an important factor that regu-
lates mtROS production.
Mitochondrial fusion
Mitochondria are dynamic organelles which frequently
change their number, size, shape, and distribution in re-
sponse to intra- and extracellular stimuli. After prolifer-
ated from pre-existing ones, fresh mitochondria enter
constant cycles of fission and fusion that can be classi-
fied into two distinct states - individual state and net-
work state. When compromised with various injuries,
solitary mitochondria are subjected to organelle degrad-
ation, which relies on autophagy, a self-eating process
that plays key roles in manifold cell activities. Recent re-
ports reveal that defects in autophagic degradation se-
lective for mitochondria (mitophagy) are associated with
neurodegenerative diseases, highlighting the physio-
logical relevance of mitophagy to cellular functions [50].
The fission and fusion processes are important for mito-
chondria to redistribute their proteins, protecting the
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(mtDNA) mutations. These processes are regulated by
N-ethylmaleimide-sensitive factor attachment protein re-
ceptor (SNARE)-like proteins which include mitofusin-1
and −2 [51]. Whether mtROS regulate mitochondrial fu-
sion remains unclear, however it has been reported that
mtROS enhance mitochondrial fragmentation [52].
Transcription factors
Several nuclear transcription factors (TFs) with well-
characterized functions in the nucleus are also present
in the mitochondria and become mitochondrial TFs
(mitoTFs). MitoTFs include those of the nuclear hor-
mone receptor family as well as TFs such as p53, nuclear
factor kappa B (NF-κB) and the signal transducer and
activator of transcription (STATs) that are activated
downstream of the binding of growth hormones and cy-
tokines to cell-surface receptors [53]. These TFs have
several different mechanisms in regulating mitochondrial
function and ROS levels. P53 can bind to the Bcl-2 fam-
ily members and induces apoptosis. Also, p53 can inhibit
SOD2. In addition, interferon regulatory transcription fac-
tor (IRF) family 3 (IRF3) can interact with proapoptotic
protein Bax. Moreover, TFs including cAMP-responsive
transcription factor (CREB), NF-κB, myocyte enhancer
factor-2D (MEF2D) and STAT3 all can regulate gene
expression.
STAT3, initially identified as a transcription factor that
regulates gene expression in response to cytokines such
as interleukin (IL)-6 and IL-10, has recently been found
to modulate mtROS through mechanisms independent
of its nuclear factor activity, but dependent on its ability
to directly modulate the activity of the ETC [13,54]. It
has been shown that STAT3 is present in the mitochon-
drial matrix, and deficiency of STAT3 in murine hearts
leads to decreased activities of complexes I and II while
increasing mtROS at complex I [13]. However, the mo-
lecular mechanism by which STAT3 modulates ETC ac-
tivity is not well understood and it remains to be
determined whether STAT3 is unique among STAT pro-
teins in localizing to mitochondrial matrix and regulat-
ing mtROS. Since STAT3 responds to cytokines of the
IL-6 and IL-10 families, which themselves regulate cellu-
lar metabolism process, it is tempting to speculate that
by modulating mitochondrial ETC activity and mtROS
generation, STAT3 links cytokine signaling pathways to
cellular metabolism.
HIF-1 mediates adaptive responses to chronic hypoxia
with reduced oxygen availability by regulating gene ex-
pression. HIF-1 reduces mtROS production under hyp-
oxic conditions by multiple mechanisms including: i) a
subunit switch in cytochrome c oxidase from the cyto-
chrome c oxidase subunit IV (COX4)-1 to COX4-2
regulatory subunit that increases the efficiency ofmitochondrial complex IV; ii) induction of pyruvate de-
hydrogenase kinase 1, which shunts pyruvate away from
the mitochondria; iii) induction of BCL2/adenovirus E1B
19 kDa protein-interacting protein 3, which triggers
mitochondrial selective autophagy; and iv) induction of
microRNA-210, which blocks assembly of Fe/S clusters
that are required for oxidative phosphorylation [55].
Epigenetic regulatory enzyme protein deacetylases
Recent progress has demonstrated that the Class III
(NAD + −dependent) deacetylases termed sirtuins play a
critical role in suppressing inflammation. Specifically,
the subcellular locations of these sirtuins including the
nucleus (SIRT-1,-2,-6,-7), cytosol (SIRT-1,-2) and mito-
chondria (SIRT-3,-4,-5) [56] suggest the important func-
tions of these Sirtuins in these locations [33,57].
Endothelial overexpression of SIRT1 has been shown to
suppress atherosclerosis and maintain normal endothe-
lial function in mice fed a high-fat diet [58] and can also
protect against hyperglycemia-induced vascular cell sen-
escence [59]. Recent progress has demonstrated that
sirtuins’ complicated regulatory functions can be acti-
vated by resveratrol, an antioxidant polyphenol com-
pound isolated from grape skin. Resveratrol has shown
promising clinical benefits as anti-aging [60], anti-
inflammatory [61], anti-diabetic [62], anti-viral [63],
anti-neoplastic [64], and anti-CVD agents [65]. Several
mechanisms underlying sirtuins functions have been
found, for example, Sirt1 induces eNOS function and
promotes NO generation. Sirt1 inhibits type 1 angiotensin
receptor and enhances tissue inhibitor of metalloproteinase.
Sirt1 also induce superoxide dismutase and other antioxi-
dant genes and suppress cellular burden of ROS.
Cytokines
As early as a decade ago, mtROS were already found to
be induced by tumor necrosis factor (TNF)-α which is
mediated by ceramide-dependent signaling pathways
[66]. However, mtROS do not appear to have a role in
TNF-α triggered NF-κB activation and ICAM-1 expres-
sion in endothelial cells [67]. It is later unveiled that
TNF-α induces a calcium-dependent increase in mtROS
that causes the shedding of TNF-α receptor-1 and re-
duces the severity of microvascular inflammation [68].
Another proinflammatory cytokine, interferon-γ (IFN-γ)
is capable of upregulating the expression of many nu-
clear genes encoding mitochondrial ETC and inducing
mtROS by activation of estrogen-related receptor alpha
(ERRα) and coactivator peroxisome proliferator-activated
receptor gamma coactivator-1 beta (PGC1β).
Adipose tissue is not only an organ of energy storage
but also an endocrine organ capable of producing a
number of cytokines termed as adipokines [69]. Two
members of the adipokine family, leptin and resistin,
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Leptin is a circulating adipokine involved in the control
of body weight. Not surprisingly, leptin could “talk” with
mitochondria and induces mtROS by increasing fatty
acid oxidation via protein kinase A (PKA) activation
[70]. Resistin is another adipocyte-derived cytokine that
play an important role in insulin resistance, adipogenesis,
and inflammation. By reducing mitochondrial Δψm and
activities of antioxidants including catalase and SOD,
resistin could induce eNOS downregulation through over-
production of mtROS in endothelial cells [71].
A recent report showed that CD8+ memory T cells,
but not CD8+ T effector (Teff ) cells, possess substantial
mitochondrial spare respiratory capacity (SRC). SRC is
an extra capacity available in cells to produce energy in
response to increased stress or work, which is associated
with cellular survival. Interleukin-15 (IL-15), a cytokine
critical for CD8+ memory T cells, regulates SRC and
oxidative metabolism by upregulating mitochondrial bio-
genesis and expression of carnitine palmitoyl transferase
(CPT1a), a metabolic enzyme that controls the rate-
limiting step to mitochondrial fatty acid oxidation
(FAO). These results demonstrate how cytokines control
the bioenergetic stability of memory T cells after infec-
tion by regulating mitochondrial metabolism [72].
In addition, IL-15 transgenic mice run twice as long
as control littermates in a run-to-exhaustion trial and
preferentially uses fat for energy metabolism. Skeletal
muscles in IL-15 transgenic mice have high expression
of intracellular mediators of oxidative metabolism
that are induced by exercise, including sirtuin 1, peroxi-
some proliferator-activated receptor (PPAR)-δ, PPAR-γ
coactivator-1α, and PPAR-γ coactivator-1β [73].Non-mitochondrial ROS sources
Under certain conditions, non-mitochondrial generated
ROS can augment mtROS production, a process known
as “ROS-induced ROS”. It has been demonstrated that
many other ROS-producing enzymes, including NADPH
oxidase [74], xanthine oxidase [75], and uncoupled
eNOS [76], can stimulate mtROS production. The
“ROS-induced ROS” system downstream of angiotensin
II (Ang II) signaling pathway is well characterized. Ang
II is a well-known stimulator of NADPH-oxidase-de-
rived ROS [77], but a role of mtROS downstream of Ang
II-mediated cellular signaling has also emerged recently
[74]. In fact, it has been suggested that by activating
NADPH oxidase, Ang II induces mtROS, which in turn
leads to further activation of NADPH oxidase. Moreover,
scavenging of mtROS using mitochondria-targeted anti-
oxidant can interrupt this vicious cycle and significantly
decrease blood pressure after the onset of Ang II-
induced hypertension [78].The question of how other sources of ROS induce
mtROS remains. However, the importance of p66shc in
this process is highlighted by the fact that p66shc is local-
ized within the mitochondrial intermembrane space and
can directly transfer electrons from cytochrome c to O2
to generate mtROS [79]. Importantly, intracellular anti-
oxidants such as GSH are thought to maintain the mito-
chondrial form of p66shc in an inactive state [80]. Thus,
p66shc may serve as a thiol-based redox sensor that sig-
nals to mitochondria to induce mtROS when the ROS
level in cytoplasm becomes high. As such, the athero-
sclerotic risk factor, oxidized LDL, activates p66shc
through NADPH oxidase [81]. Furthermore, deficiency
of p66shc gene renders mice resistant to complications of
atherosclerosis [82].
MtROS levels and signaling of mtROS
Once thought as merely the by-products of cellular me-
tabolism, mtROS are increasingly viewed as important
signaling molecules [83]. At low levels, mtROS are con-
sidered to be important for metabolic adaptation as seen
in hypoxia. Moderate levels of mtROS, stimulated by
danger signals such as Toll-like receptor 4 ligand bacter-
ial endotoxin lipopolysaccharide (LPS), are involved in
regulating inflammatory response. Finally, high levels of
mtROS activate apoptosis/autophagy pathways capable
of inducing cell death [83] (Figure 3). But, how does
mtROS signal in the cell? Much like the events of phos-
phorylation modification of proteins, mtROS promote
cell signaling via the oxidation of certain reactive cyst-
eine residues of proteins [84]. Cysteine residues can exist
in a number of oxidative states, including sulfenic form
(RSOH), sulfinic form (RSO2H), and sulphonic (RSO3H)
form. Although the pKa of most thiol group on free
cysteine is between 8 and 9, the surrounding environ-
ment of certain reactive cysteine residues can be sub-
stantially modified to result in reduced pKa as low as 4
to 5. These reactive cysteine residues (RS-) are easily oxi-
dized to RSOH. RSOH is unstable and can undergo fur-
ther oxidation into RSO2H. Furthermore, under greater
oxidative stress than that for generating RSOH and
RSO2H, RSO3H is generated. Although the generation of
RSOH and RSO2H is readily reversible, formation of
RSO3H is irreversible (Figure 4). Using computational
methods and proteomic approaches, it is suggested that
RS- might exist in more than 500 proteins, allowing
mtROS to modulate a wide variety of protein targets in
the cells [85,86].
Low mtROS
Accumulating evidence suggests that mtROS released
under hypoxic conditions regulates HIF-1α. HIF-1α is a
heterodimeric protein composed of an α subunit and a β










Figure 3 Signaling of mtROS. At low levels, mtROS participate in
the process of hypoxia adaptation by regulating the stability of
hypoxia-inducible factor 1α (HIF-1α); moderate levels of mtROS are
involved in regulating the production of proinflammatory cytokines
by directly activating the inflammasome and mitogen-activated
protein kinase (MAPK); high levels of mtROS are capable of inducing
apoptosis and autophagy by oxidation of the mitochondrial pores
and autophagy-specific gene 4 (ATG4) respectively.
Li et al. Journal of Hematology & Oncology 2013, 6:19 Page 8 of 19
http://www.jhoonline.org/content/6/1/19The stability of the α subunit, however, is regulated by
oxygen levels such that, it is stabilized under hypoxic
conditions while it undergoes proteasomal degradation
under normoxic conditions [83]. The picture is becom-
ing clear that, HIF-1α is stabilized in response to mtROS
and then feedback and inhibit the production of mtROS
[83]. The latter feedback activity is suggested by recent
identification of a mitochondrial gene, NADH dehy-
drogenase [ubiquinone] 1 alpha subcomplex, 4-like 2
(NDUFA4L2) that serves as a direct HIF-1α target [88].
Employing NDUFA4L2-silenced and NDUFA4L2 knock-
out cells, it has been demonstrated that inhibiting
mtROS generation via NDUFA4L2 upregulation induced
by HIF-1α is an essential cellular adaption process dur-
ing hypoxia.
Moderate mtROS
Several recent studies unveil the fact that mtROS act as
essential signaling molecules that regulate inflammatory
process. On one hand, one member of the cytosolic nu-
cleotide binding and oligomerization domain (NOD)-like
receptor (NLR) family, pyrin domain containing 3
(NLRP3)-containing inflammasome (caspase-1 activating
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Figure 4 Modification of proteins by ROS. ROS can oxidize specific reac
form (RSOH) of proteins. RSOH is unstable and can be further oxidized to s
(RSO3H) can be generated. Although the formation of RSOH and RSO2H isThe NLRP3 inflammasome is a multiprotein complex
consisting of the sensor protein NLRP3, the adaptor pro-
tein ASC, and the inflammatory protease precursor pre-
caspase-1 [89]. Although several sensor proteins includ-
ing NLRP3, NLRC4 (NLR family, CARD-containing 4),
AIM2 (Absent in melanoma 2), and NLRP6 (NOD-like
receptor family pyrin domain containing 6) have been
shown to form inflammasomes with caspase-1, the
NLRP3 inflammasome has drawn the most attention
due to its association with the onset and pathogenesis of
numerous inflammatory diseases [90]. Conformational
changes in NLRP3 lead to the assembly of the
inflammasome and activation of caspase-1, which pro-
motes the maturation and secretion of proinflammatory
cytokines IL-1β and IL-18. Besides its role in regulating
inflammatory processes, the NLRP3 inflammasome also
drives a form of inflammatory cell death, termed
pyroptosis [91]. In contrast to non-inflammatory apop-
tosis, pyroptosis causes local inflammation, as it is linked
to the caspase-1 cleavage of pre-IL-1 β and pre-IL-18
and release of mature IL-1β and IL-18 [92]. While apop-
totic cells retain their plasma membrane integrity until
the final stage of apoptosis, pores rapidly form in the
plasma membrane of pyroptotic cells. Such pores pro-
vide a direct route for the release of inflammatory mole-
cules including IL-1β and IL-18 [93]. Of note, it has
been shown that autophagy blockage results in accumu-
lation of dysfunctional, mtROS generating mitochondria,
which also activates the NLRP3 inflammasome [5]. In
addition, both NLRP3 and its adaptor ASC co-localize
with endoplasmic reticulum (ER) and mitochondria
upon inflammasome stimulation. However, it remains
unknown whether NLRP3 is the direct target of mtROS.
Indeed, this idea is challenged by the observation that
ROS inhibitors block priming instead of activation
of the NLRP3 inflammasome [94]. Priming of the
NLRP3 inflammasome controls the threshold of the
inflammasome activation, which involves induction
of pro-IL-1β and NLRP3 expression [89]. In this regard,
mtROS may be involved in induction of NLRP3 tran-
scripts upstream of post-translational NLRP3 activation.
Based on the differences of tissues in the expression levelsSO2HCys Cys SO3H
ROS
Sulfinic form Sulfonic form
Irreversible
tive cysteine (Cys) residues within target proteins generating sulfenic
ulfinic form (RSO2H). Under greater oxidative stress, sulfonic form
reversible, generation of RSO3H is irreversible.
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posed novel “three-tier model and inflammation privilege”
for explaining the readiness of tissues in the onset of in-
flammation in response to stimuli [95].
On the other hand, it has been shown that mtROS cause
oxidation and inactivation of MAPK phosphatases, which
results in sustained MAPK activation [96]. In addition, in-
hibition of mtROS production attenuates MAPK activa-
tion and production of IL-6 induced by LPS whereas
macrophages lacking inflammasome components produce
normal levels of IL-6 after LPS stimulation comparable to
that of wild-type macrophages [97]. Thus, in a critical
mechanistic divergence, mtROS could also regulate
inflammasome-independent proinflammatory cytokines
such as IL-6 by affecting transcription factor pathways. In-
deed, mtROS also appear to activate NF-κB and induce
the upregulation of cell surface adhesion molecules in
endothelial cells as a part of endothelial cell activation
program [67,98].
High mtROS
Similar to the caspase-1 activating inflammasomes, activa-
tion of the structurally related protein complex termed
apoptosome also requires mtROS [99]. Apoptosome is an
oligomeric structure that is assembled when apoptosis
activating factor (APAF)-1 interacts with cytochrome c
released from mitochondria, and the activation of
apoptosome initiates apoptosis by recruiting and activating
pre-caspase-9 [100]. MtROS contribute to apoptosome ac-
tivation by oxidation of the mitochondrial pores, which
leads to cytochrome c release [99]. If mtROS are involved
in both inflammasome and apoptosome activation, what
mechanisms regulate the choice of the signaling pathways?
One possibility is that the intensity or duration of mtROS
release determines the ultimate biological outcome, with
high levels of mtROS capable of inducing apoptotic
cell death.
Recent evidence yet suggests the involvement of mtROS
in the induction of autophagy, another form of pro-
grammed cell death [101]. Starvation of cells stimulates
formation of ROS, which localizes with mitochondria.
Treatment of cells with antioxidant agents abolishes
starvation-induced autophagy. Moreover, a specific react-
ive cysteine residue on autophagy regulatory protein,
autophagy-specific gene 4 (ATG4) is shown to be ROS-
sensitive. This new working model in which mtROS
oxidize ATG4 and induce autophagy requires further
examination.
Detection of mtROS by fluorescent probes
Recent progress on characterization of mtROS has been
greatly benefited from new advances in using fluores-
cence probes in the detection of mtROS. Fluorescent
dyes including dichlorodihydrofluorescein (DCF) anddihydroethidium (DHE) have been widely used to detect
intracellular ROS in early studies. While DCF is the
most widely used probe for detecting intracellular H2O2,
DHE is the most frequently used fluorescent indicator
for O2
.-. In conjugation with mitochondria-specific
markers such as MitoTracker using confocal micros-
copy, one can determine whether ROS are generated
from mitochondria [102-104]. To minimize the effect in
subtracting the fluorescence signals coming from non-
mitochondrial organelles, some fluorescence indicators
have been modified to target mitochondria specifically.
The most common way is through the use of lipophilic
cations, which are attracted to the negative potential en-
vironment caused by the proton gradient across the
inner mitochondrial membrane.
MitoSOX is a triphenylphosphonium (TPP+)-linked
DHE compound. It exploits the steep electrochemical
gradient across the mitochondrial inner membrane to
enrich the TPP-tag fluorescence more than a 100-fold
within the mitochondria compared with the cytosol
[105]. MitoSOX has been effectively used to directly de-
tect mitochondria-derived O2
.- in various cell types [106].
However, the reactions of both DHE and MitoSOX with
ROS yield two fluorescent products, one of which is O2
.-
specific, while the other is formed in response to general
oxidative stress. Thus, fluorescence microscopy or re-
lated flow cytometric techniques are not sufficient to
measure the superoxide-specific hydroxylated products
using both classical DHE and novel MitoSOX. High-
performance liquid chromatography (HPLC) methodolo-
gies are required to separate and identify these products
[78,107] (Table 2).
Appending a TPP +motif to a phenylboronate ester
generates MitoPY1 [108], which is a biologically compat-
ible probe for detecting mitochondria-derived H2O2.
MitoPY1 selectively responds to rises in H2O2 levels by
a significant fluorescence increase detected by both con-
focal microscopy and flow cytometry methods [108]. It
should be noted though: the phenylboronate moiety in
MitoPY1 also reacts with ONOO-, so MitoPY1 will re-
spond to this molecule as well.
Highly reactive oxygen species (hROS), including hy-
droxyl radical (.OH), hypochlorous acid (HOCl), and
ONOO-, are generated secondary to mtROS formation
(O2
.-, H2O2) [109]. They are highly toxic by directly oxi-
dizing nucleic acids, proteins, and lipids in the cell. .OH
originates from H2O2 through Fenton chemistry in the
presence of iron or copper centers which are prevalent
in the mitochondria. Likewise, NO produced by mito-
chondrial NOX can combine with O2
- to form ONOO-.
In addition, myeloperoxidases (MPOs) catalyze the reac-
tion of H2O2 into HOCl, which possibly could diffuse
into and damage mitochondria. As such, several probes
have been developed to detect these mitochondrial




Fluorescent probes MitoSOX Superoxide Attaching a hydrophobic cation to
dihydroethidium.
Two fluorescent products, one of which
is superoxide specific. The two
products need to be separated by HPLC.
MitoPY1 Hydrogen
peroxide
Attaching a hydrophobic cation to a
phenylboronate ester.
It also reacts with peroxynitrite.
MitoAR MitoHR Hydroxyl radical Reaction with hydroxyl radical
cleaves off the quenching motif.
They also react with peroxynitrite.
Mitochondrial
inhibitors
Rotenone Antimycin General ROS Rotenone is complex I inhibitor and
antimycin is complex III inhibitor.
Rotenone either decrease or increase










MitoDEPMPO Free radicals Free radicals have unpaired electrons,
and thus are paramagnetic and
detectable by ESR.
Lower sensitivity than fluorescent
probes.
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by attaching rhodamine-like fluorophores (which func-
tions similarly as TPP motif ) to either a 4-amino-phenyl
aryl ether or a 4-hydroxy aryl ether group, respectively.
The ether motif on both MitoAR and MitoHR quench
the fluorescence emission. Reaction with mitochondrial
hROS cleaves off the quenching motif and results in the
highly fluorescent rhodamine type reporters [110].
MitoAR mainly detects .OH and HOCl while MitoHR is
most sensitive to .OH, while both of these two probes
also react with ONOO- in a slower rate.
Detection of mtROS by other methods
ETC inhibitors and mitochondria-targeted antioxidant
Combination of traditional ROS detection method (DHE
fluorescence) with ETC inhibitors can also help to iden-
tify mtROS [111-114]. This approach is instrumental,
but the results obtained from these inhibitors are not al-
ways consistent. For example, when intact cells are used,
complex I inhibitor rotenone has been shown to either
decrease or increase ROS production [104,115]. Another
potential problem with mitochondrial inhibitors is
their interruption of the ETC, which may alter cell metabol-
ism such as ATP synthesis. In this regard, mitochondrial-
targeted antioxidants represent a promising tool in studying
mtROS. A series of antioxidants have been chemically
bonded to TPP to scavenge mtROS, including α-tocopherol
(MitoVitE) [104], nitroxides (MitoTEMPO) [78], and
ubiquinol (MitoQ) [114]. Among these, MitoQ is the best
characterized mitochondria-targeted antioxidant in animal
studies [34,105,116]. The ubiquinol form of MitoQ is oxi-
dized by mtROS to the ubiquinone form, which is quickly
re-reduced by complex II in the ETC, restoring its mtROS
scavenging capacity. In addition, the oral administration of
MitoQ is safe for at least 24 weeks in mice and rats [117].
For these reasons, orally administered MitoQ has been tested
in a number of in vivo animal studies and shown protectionagainst oxidative stress in a variety of CVD, including: hyper-
tension [118], cardiac ischemia reperfusion (I/R) injury [119],
kidney damage in type I diabetes [120], sepsis [121,122],
and endothelial damage by nitroglycerin [123].ESR
In some experiments, electron spin resonance (ESR)
spectroscopy is used to study mtROS [74,124]. Free radi-
cals such as superoxide have unpaired electrons, and
thus are paramagnetic and detectable by ESR. The appli-
cation of different spin probes, cell permeable versus
nonpermeable, allows one to localize and distinguish
mtROS versus non-mtROS and intracellular versus extra-
cellular ROS. Another advantage of ESR assay is that cells
or tissue samples can be frozen and analyzed later. In
addition, ESR has potential in determining the chemical
identities of ROS. For example, MitoDEPMPO has been
developed as a mitochondria-targeted nitrone traps for
ESR detection of mitochondria-derived superoxide [125].
Moreover, it can be used to analyze cells in suspension.
However, the sensitivity of ESR assay is lower than that of
methods based on fluorescence. Moreover, ESR assay can-
not be applied for ROS detection and determination of
intracellular distribution in a single cell (Table 2).
MtROS in vascular cells
Endothelial cells (ECs)
Even when plenty of oxygen is presented, ECs rely heav-
ily on glycolysis rather than OXPHOS-mitochondrial
respiration to generate ATP [126]. Nevertheless, ECs still
contain functional mitochondria, in which oxidative
phosphorylation continues [127,128]. Thus, the primary
function of mitochondria in ECs may be the regulated
generation of ROS for cells signaling purpose, but not
generation of ATP for energy production. If this is true,
ECs could modulate mtROS production without jeopardizing

















Figure 5 Role of endothelial mtROS in atherosclerosis.
Pathologic stressors as diverse as oxidized low-density lipoproteins
(oxLDL), glucose, and Angiotensin II are all capable of inducing mtROS
in endothelial cells through their receptors. Excessive mtROS then
directly bind to NO and induce endothelial cell dysfunction.
Overproduction of mtROS also leads to activation of proinflammatory
transcription factors such as nuclear factor kappa B (NFκB). This in turn
increases the expression of adhesion molecules and production of
inflammatory cytokines in endothelial cells, both of which contribute
to the development of atherosclerosis. LOX-1: lectin-type oxidized LDL
receptor 1; TLRs: Toll-like receptors; AT1R: Angiotensin II receptor, type
1; GLUT4: glucose transporter type 4.
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a variety of important endothelial functions under basal condi-
tions whereas activating proinflammatory pathways in re-
sponse to cardiovascular risk factors in ECs [129].
Under normal physiological conditions, mtROS are
capable of regulating vascular homeostasis. Firstly, it has
been demonstrated that vascular endothelial growth fac-
tor (VEGF) promotes endothelial migration through
mtROS in cultured human umbilical vein endothelial
cells [130]. Endothelial migration is critical in a variety
of physiological conditions including wound healing and
vascular repair. VEGF increases mitochondrial metabol-
ism and mtROS production. Furthermore, mitochondria-
targeted antioxidant prevents VEGF-induced endothelial
migration. Secondly, mtROS contribute to endothelium-
dependent vasodilation [131]. The endothelium regulates
vascular homeostasis in response to shear stress by syn-
thesizing vasodilators such as NO. Using ESR and
histochemofluorescence methods, it has been shown that
shear flow increases the production of ROS in human
coronary resistance arteries, which can be blocked by
mitochondrial complex I inhibitor rotenone. Moreover,
complex I and complex III inhibitors, but not NADPH
oxidase inhibitors, markedly blocked flow-induced dila-
tion. Notably, ROS formation in response to flow after
endothelial denudation is significantly decreased, suggesting
an important role of endothelium in flow-induced mtROS
formation. Thirdly, mtROS are also of importance in
hypoxia-induced adaptation response in ECs. At low
O2 concentrations, mitochondria of HUVECs (human
umbilical vein endothelial cells) have been shown to gener-
ate ROS for activation of enzymes such as AMPK
(AMP-activated protein kinase) because: 1) AMPK activa-
tion coincides with the hypoxia condition at which ROS is
produced; 2) antioxidants can rescue hypoxia-induced
AMPK activation; and 3) AMPK activation does not occur
in ρ0 HUVECs devoid of mitochondria. Under the chal-
lenge of cardiovascular risk factors, however, excessive
mtROS are produced in endothelial mitochondria. Vascular
stressors, as diverse as oxidized lipids, high glucose, and
angiotensin II, can all induce mtROS in ECs. (Figure 5,
Table 3).
Oxidized low density lipoprotein (oxLDL). Substantial
evidence suggests that the retention and oxidative modi-
fication of LDL and subsequently activation of ECs initi-
ates atherosclerotic lesion formation [132]. OxLDL
triggers the expression of adhesion molecules and secre-
tion of chemokines by ECs, which drive immune cell in-
filtration. In this sense, oxLDL has been shown to
induce mtROS in ECs in vitro [102,133,134]. Using con-
focal microscopy, it has been demonstrated that a sig-
nificant proportion of oxLDL-induced cellular ROS are
co-localized to mitochondria. Moreover, ECs that are de-
ficient in functional mitochondria show a substantialdecrease in cellular ROS formation stimulated by oxLDL
[102]. The precise mechanisms whereby oxLDL induces
excessive mtROS generation in ECs remains poorly de-
fined. It has been suggested that oxLDL significantly re-
duces oxygen consumption and enzyme activity in the
mitochondrial ETC [133]. OxLDL also increases mito-
chondrial membrane potential and reduces SOD2 pro-
tein levels [134]. Moreover, c-Jun N-terminal kinases
(JNK, one of the MAPKs) small interference RNA (siJNK)
reduces oxLDL induced mtROS production substantially.
OxLDL contains highly heterogeneous mixtures of bio-
logically active substances [135]. Lysophosphatidylcholine
(LysoPC, one of the active component derived from
oxLDL) accounts for nearly 50% of the phosphatidylcho-
line equivalents in oxLDL and is considered as a critical
factor that contributes to the proatherogenic activity of
oxLDL [136]. As such, one study suggests that ROS pro-
duction by lysoPC occurs predominantly in the mitochon-
dria and is associated with an increase in mitochondrial
Ca2+ uptake [104].
Hyperglycemia-high glucose. Hyperglycemia is a key
cardiovascular risk factor for patients with type 2 diabetes
[137]. High glucose is the first identified pathogenic
Table 3 Identified pathologic stressors that induce mtROS in endothelial cells (ECs)
Cell type Treatment Dose Time PMID
Bovine aortic ECs Oxidized LDL 200 μg/ml 30 min 15805232
Bovine aortic ECs Electrophilic lipids 4 μM 4 h 16387790
Human umbilical vein ECs LysoPC 5 μmol/L 60 min 16651638
Porcine aortic ECs Glycated LDL 100 μg/ml 2 h 20036735
Bovine aortic ECs Glucose 30 mM 2 h 10783895
Human aorta ECs Glucose 25 mM 7 d 12600878
bEnd3 microvascular ECs Glucose 40 mM 7 d 21808008
Human umbilical vein ECs Low Glucose ≤ 80 mg/dL 5 min 22207730
Bovine aortic ECs Angiotensin II 200 nmol/L 4 h 18096818
Human aortic ECs Angiotensin II 200 nmol/L 4 h 20448215
Human aortic ECs Homocysteine 150 μM 24 h 21672628
Human umbilical vein ECs Hypoxia 14 mmHg 30 min 11950692
Human umbilical vein ECs Hypoxia 0 mmHg 24 h 12165534
Porcine aortic ECs Hypoxia 0 mmHg 1 h 12690038
Murine pulmonary ECs Thrombin 1 mU/mL 100 s 17724077
Human umbilical vein ECs PAR1-AP 50 μmol/L 1 h 18983479
Human umbilical vein ECs TNF-α 1 ng/mL 1 h 11415943
Murine pulmonary ECs TNF-α 1 ng/mL 10 min 21519143
Bovine aortic ECs Leptin 10 ng/mL 45 min 11342529
Human coronary artery ECs Resistin 40/80 ng/mL 24 h 20435848
Human umbilical vein ECs VEGF 50 ng/mL 5 min 21653897
PMID: PubMed ID.
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induced DCF fluorescence in bovine aortic ECs is
prevented by several factors including an inhibitor of the
ETC complex, an uncoupler of oxidative phosphorylation,
uncoupling protein-1 and SOD2 [111]. Furthermore, nor-
malizing levels of mtROS after treatment of cells with
each of these agents prevents high glucose-induced activa-
tion of protein kinase C, formation of advanced glycation
end-products, sorbitol accumulation and NFκB activation
[111]. Later on, other studies report similar results
[112,138]. One study shows that inhibition of ROS
production by uncoupling of the ETC significantly
reduces high glucose-mediated induction of IL-8 expres-
sion in human aortic ECs [112]. Another study links high
glucose-dependent mtROS to increased consumption of
H2S [138]. Interestingly, traditional pharmacological
drugs including anti-inflammatory Sirt1 activator resvera-
trol, anti-inflammatory/anti-cancer drug cannabidiol, and
hypolipidemic drug simvastatin have been shown to
prevent high glucose-induced mtROS [139-141]. The meas-
urement of MitoSOX fluorescence shows that resveratrol
attenuates high glucose-induced mtROS production in
human coronary arterial ECs. The authors propose that
resveratrol, via a pathway that involves the upregulation
of antioxidant defense mechanism, attenuates mtROSproduction [139]. Another paper shows that high glucose
markedly increases mtROS, NF-κB activation, upregulation
of iNOS, and EC adhesion molecules intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-
1 (VCAM-1), transendothelial migration of monocytes, and
monocyte-endothelial adhesion in human coronary artery
ECs. Remarkably, all the above mentioned effects induced
by high glucose are attenuated by cannabidiol pretreatment
[140]. Similarly, Simvastatin decreases high glucose-
induced mtROS in bovine retinal capillary ECs and exerts
protective effects against early retinal vascular damage in
diabetic rats [141]. A recent study proposes that acute
exposure to low glucose also increases mtROS production
in human umbilical vein ECs [142]. Interestingly, anti-
diabetic drug Metformin can reverse low glucose-induced
endothelial dysfunction through inhibiting excessive
mtROS production.
Angiotensin II. Ang II is another pathogenic stressor
that mediates endothelial dysfunction and promotes vas-
cular inflammation and atherogenesis [143]. Ang II
treatment of bovine aortic ECs is shown to significantly
increase mtROS production detected by ESR. This effect
is associated with decreased endothelial NO availability
[74]. Later on, the same group confirms this result using
MitoSOX fluorescent probe. Interestingly, supplementation
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oxidant mitoTEMPO abolishes the MitoSOX signal after
Ang II stimulation [78]. In addition, mitoTEMPO also
prevents the loss of endothelial NO caused by Ang II both
in cultured ECs and intact mice. Furthermore, treatment
of hypertensive mice with mitoTEMPO after onset of Ang
II-induced hypertension significantly reduces blood pres-
sure and substantially improves endothelium-dependent
vasodilation.
Macrophages (MΦ) and dendritic cells (DCs)
The mononuclear phagocytic system consists of mono-
cytes, MΦ, and DCs [144]. These cells all originate from
the same haematopoietic precursors located in the bone
marrow and their main functions are phagocytosis, cyto-
kine secretion and antigen presentation. MΦ and DCs
precursors are released into the circulation as mono-
cytes, and within several days they exit the circulation
through the endothelium into body tissues and differen-
tiate into mature MΦ and DCs.
The phagocytic response of MΦ involves the produc-
tion of ROS via NADPH-oxidase-dependent respiratory
burst. However, recent studies have suggested that
mtROS also have an important role in MΦ innate im-
mune response [145]. Activation of a subset of Toll-like
receptors (TLR1, TLR2, and TLR4) results in the recruit-
ment of mitochondria to MΦ phagosomes and increased
production of mtROS. This augmentation of mtROS
production involves the engagement of a TLR signaling
adaptor, tumor necrosis factor receptor-associated factor
6 (TRAF6), and the protein evolutionarily conserved sig-
naling intermediate in Toll pathways) in the mitochon-
dria. ECSIT is implicated in mitochondrial ETC
assembly. Interaction between the two molecules then
leads to ECSIT ubiquitination and enrichment around
mitochondria, resulting in increased mtROS production.
Additionally, scavenging mtROS in MΦ by expressing
catalase in the mitochondria results in defective bacterial
killing, confirming the important role of mtROS in MΦ
bactericidal activity.
DCs are potent antigen-presenting cells, capable of in-
ducing T and B responses as well as immune tolerance.
Compare to its precursor monocytes, DCs exhibit sig-
nificantly larger number of mitochondria and higher en-
dogenous respiratory activity [146]. Complex I inhibitor
rotenone prevents the increase in mitochondrial number
as well as DC differentiation. Moreover, rotenone and
catalase treatment both inhibit growth factor-induced
mtROS in DCs, indicating that the differentiation of DC
can be regulated by mtROS in DCs.
Smooth muscle cells (SMCs)
Vascular SMCs migrate and proliferate when they are
stimulated by cytokines and fibrogenic factors [147].MtROS play an important role in this process as demon-
strated by the finding that they mediate the activation of
Akt/NFκB signaling pathway in response to 4-
hydrocynonenal (4-HNE) stimulation in vascular SMCs
[148]. In addition, mtROS in SMCs also play a role in
cold-induced constriction of cutaneous arteries [149].
Cold constricts cutaneous arteries by selectively increas-
ing the activity of α2-adrenoceptors (α2-ARs). Complex I
inhibitor rotenone can abolish cold-induced increase in
α2-ARs activity and dramatically inhibits cold-induced
constriction response as well. In the atherosclerotic dis-
ease setting, thickened plaques render vascular SMCs
prone to be hypoxic because of poor perfusion. Complex
I inhibitor rotenone again abolishes hypoxia-induced
HIF-1α protein expression and ROS generation,
suggesting a critical role of mtROS in this pathological
condition [150].MtROS and cancers
Mitochondria lie at the center of the metabolic theory of
cancer [151]. Normally, differentiated cells primarily rely
on mitochondrial respiration to produce ATP in the
presence of oxygen (generating 36 mol. ATP/mol. glu-
cose). Only under limited oxygen availability will healthy
cells rely on anaerobic glycolysis as their energy source
(generating 2 mol. ATP/mol. glucose). However, most
cancer cells adopt the way of “aerobic glycolysis” for en-
ergy production [151]. This phenomenon, also known as
the Warburg effect [152], is initially confusing to scien-
tists as it is highly energy inefficient. However, it was
later found that cancer cells have other important meta-
bolic requirements that extend beyond the generation of
ATP. On one aspect, cancer cells are particularly
challenged in dealing with oxidative stress [153]. In
highly proliferative cancer cells, the presence of
oncogenic mutations promotes aberrant metabolism
and protein translation, resulting in increased rates
of ROS production. It was found that the Warburg
effect is beneficial to transformed cells by upregulating
antioxidant systems to counteract the accumulation
of ROS. One key glycolytic enzyme – pyruvate kin-
ase, plays an important role in this process: tumor
cells express exclusively the embryonic M2 isoform
of this enzyme (PKM2) [154] and an increase in
intracellular ROS can inhibit PKM2 by oxidation of
one reactive cysteine residue in this enzyme [155].
This inhibition of PKM2 then leads to the produc-
tion of reducing equivalents to detoxify ROS by di-
verting glucose metabolism into pentose phosphate
pathway [155]. By doing this, the regulatory proper-
ties of PKM2 provide cancer cells the protection
against excessive mtROS production commonly seen
in cancer [156].
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Hypertension is associated with increased ROS production
in several key target organs, including the vasculature, the
kidney, and the central nervous system, which all contrib-
ute to the regulation of blood pressure [157]. Ang II, the
hormone commonly implicated in hypertension, is shown
to increase ROS production in these sites. A key role of
NADPH oxidase in this process has been demonstrated
both in vitro and in vivo [158]. However, later studies indi-
cates that Ang II activation of NADPH oxidase further
leads to mitochondrial dysfunction and increased mtROS
production [74]. Importantly, mice transgenic for Trx2,
the mitochondrial antioxidant enzyme, are shown to resist
the development of Ang II-induced hypertension and
endothelial dysfunction [159]. Moreover, Ang II-induced
hypertension is also significantly attenuated by either
overexpressing SOD2 or treatment with mitoTEMPO
[78]. These studies strongly demonstrate the potential of
antioxidant strategies specifically targeting mitochondria
as therapy in hypertension and possibly other diseases.
MtROS and atherosclerosis
Multiple lines of in vivo experimental data indicate that
excessive mtROS within vasculature promote the develop-
ment of atherosclerosis. ApoE−/− mice that are deficient in
SOD2, a mitochondria-specific antioxidant enzyme, ex-
hibit accelerated atherogenesis at arterial branching points
[160]. SOD2 is also shown to protect against endothelial
dysfunction in carotid artery of ApoE−/− mice [20]. Not-
ably, transgenic overexpression of Trx2, another mito-
chondrial antioxidant enzyme, improves endothelial
function and reduces atherosclerotic lesions in ApoE−/−
mice in part by reducing oxidative stress and increasing
NO bioavailability [27]. There is still limited knowledge of
the involvement of mtROS in human atherogenesis; how-
ever, epidemiologic data suggest that genetic nucleotide
polymorphisms leading to reduced SOD2 function are as-
sociated with increased atherosclerotic risk [161]. In
addition, there is significantly increased mtDNA damage
in atherosclerotic human arterial specimens compared to
that of normal human arterial tissue [160]. Indeed, in-
creased mtDNA damage is also a shared phenotype of
multiple diseases including neurological degenerative dis-
ease [162] and cancer [163]. As mtDNA contains genes
that encode critical structural subunits for three of the
four protein complexes of the ETC (complex I, III, and
IV) (Table 1) [164], mtDNA damage will lead to increases
in mtROS generation and the extent of mtDNA damage is
an index of the levels of mtROS.
MtROS and other inflammatory diseases
It has long been recognized that ROS are implicated in
many inflammatory diseases other than atherosclerosis,
including multiple sclerosis [165], rheumatoid arthritis[166], thyroiditis [167], and type 1 diabetes [168]. Very re-
cently, however, it has been identified that mitochondria-
derived ROS rather than NADPH oxidase-derived ROS
promote the production of proinflammatory cytokines in
TNFR1-associated periodic syndrome (TRAPS) [6].
TRAPS is an autoinflammatory disorder associated with
enhanced innate immune responsiveness. It is caused by
mutations of the gene encoding type 1 TNF receptor
(TNFR1), which leads to aberrant activation of MAPKs
[169]. It has been found that mtROS, mitochondrial oxi-
dative capacity, and Δψm are all increased in human pa-
tient cells and mouse cells harboring TRAPS-related
TNFR1 mutations [6]. Moreover, scavenging mtROS using
MitoQ abolishes inflammatory cytokine production after
LPS stimulation in these cells, highlighting the potential of
targeting mtROS as novel therapy for TRAPS and other
inflammatory diseases.Conclusions
Oxidative stress has long been recognized as a major
player in the development of atherosclerosis and other
inflammatory diseases. This has led to the enthusiastic
use of antioxidants in the prevention and treatment of
diseases. However, the results of randomized clinical tri-
als of Vitamin C and Vitamin E have been disappointing
[170-173]. If indeed oxidative stress is so crucial in the
development and manifestations of atherosclerosis-
related diseases including myocardial infarction and
stroke, why have so many clinical trials failed to demon-
strate its therapeutic efficacy? One possibility may be re-
lated to the fact that only a small proportion of known
antioxidants in vivo are actually located in the mito-
chondria. Given the fact that mtROS directly drive
proinflammatory cytokine production, we can speculate
that specific targeting of mtROS may result in better
outcome in combating chronic inflammatory diseases
such as atherosclerosis. However, in order to translate
this knowledge from benchtop to bedside, future studies
that fully characterize the biochemistry of mtROS and
the specific role mtROS plays in these inflammatory dis-
eases need to be performed. We hope that our review
will encourage investigators to enter this important field
of research and to accelerate the pace of translational
medicine and therapeutics.
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